Baker Brothers portfolio, Q2 2025

Baker Bros. Advisors · 13F for the quarter ending Jun 30, 2025

For Q2 2025, Baker Bros. Advisors reported $10.3B across 89 US-listed positions, led by ONC (20.7%), INCY (20.3%) and ACAD (9.0%). Compared with its filing for Q1 2025, Baker Brothers opened 12 new positions, added to 23, reduced 8 and sold out of 12; 46 positions did not change.

The largest purchase was an addition to INSM ($234.7M); the largest sale, the sale of the whole position in Insmed Inc ($101.6M).

Reported value
$10.3B
Positions
89
In the top 10
82%
Filed
Aug 14
2025

Key facts

13F portfolio value
$10.3BQ2 2025
Positions
89
Largest holding
ONC 20.7%
New positions
12
Sold out
12
Filed
Aug 14, 2025

Holdings as of (Q2 2025), filed with the SEC on . Changes are measured against the filing for Mar 31, 2025. Every tracked investor's Q2 2025 13F.

Bought and sold in Q2 2025

Baker Brothers: buys and sells in Q2 2025
StockMoveSharesSizeOf portfolio
Insmed IncINSM▲ Added 43%+2.33M$234.7M2.28%
Summit Therapeutics IncSMMT▲ Added 38%+9.3M$197.9M1.92%
Insmed Incno ticker on file
▼ Sold out—$101.6M0.99%
Alkermes PLCALKS▲ Added 43%+1.93M$55.1M0.53%
Revolution Medicines IncRVMD▲ Added 18%+1.43M$52.5M0.51%
Structure Therapeutics IncGPCR▲ Added 594%+2.15M$44.5M0.43%
Ultragenyx PharmaceuticalRARE▲ Added 76%+1.2M$43.5M0.42%
BioNTech SEBNTX▲ Added 719%+323.89K$34.5M0.33%
Kymera Therapeutics IncKYMR▲ Added 11%+655.5K$28.6M0.28%
Viridian Therapeutics IncVRDN▲ New+1.74M$24.4M0.24%
CRISPR Therapeutics AGCRSP▼ Sold out−654.1K$22.3M0.22%
IDEAYA Biosciences IncIDYA▲ Added 99%+1.06M$22.2M0.22%
argenx SEARGX▼ Reduced 51%−40K$22M0.21%
Intellia Therapeutics IncNTLA▲ Added 315%+2.03M$19.1M0.18%
Merus N Vno ticker on file
▲ Added 157%+350.88K$18.5M0.18%
Centessa Pharmaceuticals PLCno ticker on file
▼ Sold out−1.23M$17.6M0.17%
Blueprint Medicines Corpno ticker on file
▲ New+125.54K$16.1M0.16%
Celcuity IncCELC▲ Added 28%+1.19M$15.9M0.15%
Immatics N.V.IMTX▲ Added 40%+2.89M$15.6M0.15%
Edgewise Therapeutics IncEWTX▲ Added 19%+1.15M$15.1M0.15%
Praxis Precision MedicinesPRAX▲ Added 108%+357.96K$15.1M0.15%
Arrowhead PharmaceuticalsARWR▲ New+939.17K$14.8M0.14%
Dianthus Therapeutics IncDNTH▲ New+789.76K$14.7M0.14%
Disc Medicine IncIRON▲ Added 337%+260K$13.8M0.13%
2seventy bio Incno ticker on file
▼ Sold out−2.5M$12.3M0.12%
Akero Therapeutics Incno ticker on file
▼ Reduced 41%−224.08K$12M0.12%
Cidara Therapeutics Incno ticker on file
▲ New+227.27K$11.1M0.11%
Arcellx Incno ticker on file
▲ New+166.83K$11M0.11%
Nuvalent Incno ticker on file
▲ New+143.94K$11M0.11%
Bicara Therapeutics IncBCAX▼ Sold out−833.33K$10.9M0.11%
Ionis Pharmaceuticals IncIONS▼ Sold out−357.92K$10.8M0.10%
Candel Therapeutics IncCADL▼ Reduced 85%−2.08M$10.5M0.10%
Spyre Therapeutics IncSYRE▲ New+626.7K$9.4M0.09%
Cerus CorpCERS▼ Reduced 33%−6.47M$9.1M0.09%
Celldex Therapeutics IncCLDX▲ Added 169%+417.73K$8.5M0.08%
Crinetics Pharmaceuticalsno ticker on file
▲ New+280K$8.1M0.08%
CytomX Therapeutics IncCTMX▲ New+3.48M$7.9M0.08%
Neurogene IncNGNE▼ Reduced 33%−494.51K$7.4M0.07%
Dyne Therapeutics IncDYN▼ Sold out−672.1K$7M0.07%
Agios Pharmaceuticals IncAGIO▲ New+189.87K$6.3M0.06%
Rapport Therapeutics IncRAPP▲ New+550.09K$6.3M0.06%
Regulus Therapeutics Incno ticker on file
▼ Sold out−2.69M$4.7M0.05%
Prime Medicine IncPRME▼ Sold out−1.03M$2M0.02%
Rocket Pharmaceuticals IncRCKT▼ Reduced 50%−545K$1.3M0.01%
Compass Therapeutics IncCMPX▼ Sold out−547.5K$1M0.01%
Fate Therapeutics IncFATE▼ Reduced 24%−773.38K$866.2K0.01%
Xenon Pharmaceuticals IncXENE▲ Added 6.6%+22.8K$713.6K0.01%
Madrigal Pharmaceuticals IncMDGL▲ Added 0.07%+1.43K$432.2K0.00%
Acadia Pharmaceuticals IncACAD▲ Added 0.04%+18.77K$405K0.00%
Incyte CorpINCY▲ Added 0.01%+3.32K$226.2K0.00%
Kiniksa Pharmaceuticals InternationalKNSA▲ Added 0.2%+6.35K$175.6K0.00%
Leap Therapeutics Incno ticker on file
▼ Sold out−404.74K$123.5K0.00%
Century Therapeutics IncIPSC▼ Sold out−241.68K$115K0.00%
Design Therapeutics IncDSGN▼ Reduced 1.8%−30.84K$103.9K0.00%
IGM Biosciences Incno ticker on file
▲ Added 0.02%+953$1.1K0.00%

Holdings at the quarter's end

Baker Brothers holdings, Q2 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q1 2025
1Beone Medicines LtdONC · SPONSORED ADSHealth Care20.7%$2.1B8.8M$242.075+ qtrsNo change
2Incyte CorpINCYHealth Care20.3%$2.1B30.74M$68.105+ qtrs▲ Added 0.01%
3Acadia Pharmaceuticals IncACAD—8.98%$925.3M42.9M$21.575+ qtrs▲ Added 0.04%
4Insmed IncINSMHealth Care7.53%$776.2M7.71M$100.645+ qtrs▲ Added 43%
5Summit Therapeutics IncSMMTHealth Care6.96%$717.6M33.72M$21.285+ qtrs▲ Added 38%
6Madrigal Pharmaceuticals IncMDGLHealth Care5.80%$598M1.98M$302.645+ qtrs▲ Added 0.07%
7Rhythm Pharmaceuticals IncRYTMHealth Care3.44%$354.1M5.6M$63.195+ qtrsNo change
8Revolution Medicines IncRVMDHealth Care3.34%$344.5M9.36M$36.795+ qtrs▲ Added 18%
9Kymera Therapeutics IncKYMRHealth Care2.82%$290.3M6.65M$43.645+ qtrs▲ Added 11%
10Alkermes PLCALKS · SHSHealth Care1.78%$183.4M6.41M$28.615+ qtrs▲ Added 43%
11Replimune Group IncREPL—1.00%$102.6M11.05M$9.295+ qtrsNo change
12Ultragenyx PharmaceuticalRARE—0.98%$100.8M2.77M$36.365+ qtrs▲ Added 76%
13Edgewise Therapeutics IncEWTXHealth Care0.93%$95.8M7.31M$13.115+ qtrs▲ Added 19%
14Abcellera Biologics IncABCL—0.92%$94.4M27.53M$3.435+ qtrsNo change
15Immunovant IncIMVTHealth Care0.85%$87.3M5.46M$16.005+ qtrsNo change
16Grail IncGRALHealth Care0.81%$83.8M1.63M$51.423 qtrsNo change
17Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.76%$78.2M2.82M$27.675+ qtrs▲ Added 0.2%
18Bicycle Therapeutics PlcBCYC · SPONSORED ADS—0.73%$75.7M10.89M$6.955+ qtrsNo change
19Immunocore Holdings plcIMCR · ADS—0.71%$72.9M2.32M$31.385+ qtrsNo change
20Celcuity IncCELC—0.71%$72.8M5.45M$13.355+ qtrs▲ Added 28%
21Kodiak Sciences IncKODHealth Care0.63%$64.6M17.31M$3.735+ qtrsNo change
22Immatics N.V.IMTX · SHS—0.53%$54.7M10.17M$5.385+ qtrs▲ Added 40%
23Stoke Therapeutics IncSTOK—0.51%$52.6M4.63M$11.355+ qtrsNo change
24Denali Therapeutics IncDNLI—0.51%$52.2M3.73M$13.995+ qtrsNo change
25Structure Therapeutics IncGPCR · SPONSORED ADS—0.51%$52M2.51M$20.744 qtrs▲ Added 594%
26IDEAYA Biosciences IncIDYA—0.43%$44.5M2.12M$21.025+ qtrs▲ Added 99%
27Nurix Therapeutics IncNRIX—0.43%$44.2M3.88M$11.395+ qtrsNo change
28Roivant Sciences LtdROIV · SHSHealth Care0.41%$42.5M3.77M$11.275+ qtrsNo change
29BioNTech SEBNTX · SPONSORED ADSHealth Care0.38%$39.3M368.92K$106.473 qtrs▲ Added 719%
30Entrada Therapeutics IncTRDA—0.32%$32.7M4.87M$6.725+ qtrsNo change
31
Merus N Vno ticker on file
—0.29%$30.2M574.38K$52.605+ qtrs▲ Added 157%
32Praxis Precision MedicinesPRAXHealth Care0.28%$29M689.49K$42.055+ qtrs▲ Added 108%
33Intellia Therapeutics IncNTLA—0.24%$25.1M2.68M$9.383 qtrs▲ Added 315%
34Viridian Therapeutics IncVRDN—0.24%$24.4M1.74M$13.981 qtrNew
35Monte Rosa Therapeutics IncGLUE—0.22%$22.2M4.92M$4.515+ qtrsNo change
36
Verona Pharma Plcno ticker on file · SPONSORED ADS
—0.21%$21.2M223.84K$94.582 qtrsNo change
37Vaxcyte IncPCVXHealth Care0.20%$20.8M640.89K$32.515+ qtrsNo change
38argenx SEARGX · SPONSORED ADRHealth Care0.20%$20.8M37.76K$551.225+ qtrs▼ Reduced 51%
39
Verve Therapeutics Incno ticker on file
—0.18%$19M1.69M$11.235+ qtrsNo change
40Cerus CorpCERS—0.18%$18.2M12.88M$1.415+ qtrs▼ Reduced 33%
41Disc Medicine IncIRON—0.17%$17.9M337.05K$52.963 qtrs▲ Added 337%
42
Akero Therapeutics Incno ticker on file
—0.17%$17.3M324.63K$53.365+ qtrs▼ Reduced 41%
43
Blueprint Medicines Corpno ticker on file
—0.16%$16.1M125.54K$128.181 qtrNew
44Sera Prognostics IncSERA · CLASS A COM—0.15%$15.2M5.5M$2.775+ qtrsNo change
45Arrowhead PharmaceuticalsARWRHealth Care0.14%$14.8M939.17K$15.801 qtrNew
46Neurogene IncNGNE—0.14%$14.8M991.69K$14.955+ qtrs▼ Reduced 33%
47Dianthus Therapeutics IncDNTHHealth Care0.14%$14.7M789.76K$18.631 qtrNew
48Celldex Therapeutics IncCLDX—0.13%$13.5M665.37K$20.355+ qtrs▲ Added 169%
49Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.13%$13.4M1.46M$9.165+ qtrsNo change
50Xenon Pharmaceuticals IncXENE—0.11%$11.6M370.21K$31.305+ qtrs▲ Added 6.6%
51
Cidara Therapeutics Incno ticker on file
—0.11%$11.1M227.27K$48.711 qtrNew
52
Arcellx Incno ticker on file
—0.11%$11M166.83K$65.851 qtrNew
53
Nuvalent Incno ticker on file
—0.11%$11M143.94K$76.301 qtrNew
54Spyre Therapeutics IncSYREHealth Care0.09%$9.4M626.7K$14.971 qtrNew
55Taysha Gene Therapies IncTSHA—0.09%$9.3M4M$2.315+ qtrsNo change
56Prelude Therapeutics IncPRLD—0.08%$8.2M10.12M$0.80945+ qtrsNo change
57
Crinetics Pharmaceuticalsno ticker on file
—0.08%$8.1M280K$28.761 qtrNew
58CytomX Therapeutics IncCTMX—0.08%$7.9M3.48M$2.271 qtrNew
59Sagimet Biosciences IncSGMT—0.07%$7.3M953K$7.625+ qtrsNo change
60Sionna Therapeutics IncSION—0.07%$6.9M400K$17.352 qtrsNo change
61Agios Pharmaceuticals IncAGIO—0.06%$6.3M189.87K$33.261 qtrNew
62Rapport Therapeutics IncRAPP—0.06%$6.3M550.09K$11.371 qtrNew
63Skye Bioscience IncSKYE—0.06%$6.1M1.45M$4.185+ qtrsNo change
64Design Therapeutics IncDSGN—0.06%$5.8M1.71M$3.375+ qtrs▼ Reduced 1.8%
65KALA BIO IncKALA—0.06%$5.7M1.2M$4.765+ qtrsNo change
66Sana Biotechnology IncSANA—0.05%$5.5M2.03M$2.735+ qtrsNo change
67Xencor IncXNCR—0.05%$5.3M670.43K$7.865+ qtrsNo change
68Alumis IncALMS—0.05%$4.7M1.56M$3.005+ qtrsNo change
69
IGM Biosciences Incno ticker on file
—0.05%$4.6M4.1M$1.125+ qtrs▲ Added 0.02%
70TScan Therapeutics IncTCRX—0.04%$4M2.78M$1.455+ qtrsNo change
71Relay Therapeutics IncRLAY—0.04%$4M1.16M$3.465+ qtrsNo change
72Fate Therapeutics IncFATE—0.03%$2.8M2.49M$1.125+ qtrs▼ Reduced 24%
73Vir Biotechnology IncVIR—0.03%$2.7M542.54K$5.043 qtrsNo change
74Enliven Therapeutics IncELVN—0.02%$2.3M114.83K$20.065+ qtrsNo change
75Wave Life Sciences LtdWVE · SHS—0.02%$2.2M344.06K$6.504 qtrsNo change
76Tectonic Therapeutic IncTECX—0.02%$2M100K$19.872 qtrsNo change
77Candel Therapeutics IncCADL—0.02%$1.8M355.11K$5.063 qtrs▼ Reduced 85%
78Protara Therapeutics IncTARA—0.02%$1.6M536.83K$3.035+ qtrsNo change
79vTv Therapeutics IncVTVT · CL A—0.01%$1.5M97.31K$15.005+ qtrsNo change
80Rocket Pharmaceuticals IncRCKT—0.01%$1.4M552.08K$2.453 qtrs▼ Reduced 50%
81Contineum Therapeutics IncCTNM · CL A—0.01%$1.2M312.5K$3.975+ qtrsNo change
82
HOOKIPA Pharma Incno ticker on file
—0.01%$1M812.81K$1.265+ qtrsNo change
83Neumora Therapeutics IncNMRA—0.01%$758.7K1.03M$0.73335+ qtrsNo change
84
Generation Bio Cono ticker on file
—0.01%$622.6K1.94M$0.32015+ qtrsNo change
85Aligos Therapeutics IncALGS—0.01%$598.8K83.06K$7.215+ qtrsNo change
86Tyra Biosciences IncTYRA—0.00%$101.5K10.61K$9.575+ qtrsNo change
87Acrivon Therapeutics IncACRV—0.00%$27.1K22.81K$1.195+ qtrsNo change
88
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$15.1K833.33K$0.01815+ qtrsNo change
89
Opthea Limitedno ticker on file · SPONSORED ADS
—0.00%$02.09M—5+ qtrsNo change

By sector

Baker Brothers portfolio by sector, Q2 2025
SectorShare of portfolioValuePositions
Health Care78.5%$8.1B22
No sector on file21.5%$2.2B67

Questions and answers

What did Baker Brothers own in Q2 2025?

Baker Bros. Advisors's 13F for Q2 2025 lists 89 positions worth $10.3B. The largest: ONC (20.7%), INCY (20.3%), ACAD (9.0%), INSM (7.5%), SMMT (7.0%).

What did Baker Brothers buy in Q2 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: INSM (added, $234.7M), SMMT (added, $197.9M), ALKS (added, $55.1M), RVMD (added, $52.5M), GPCR (added, $44.5M), RARE (added, $43.5M).

What did Baker Brothers sell in Q2 2025?

The largest sales: Insmed Inc (sold out, $101.6M), CRSP (sold out, $22.3M), ARGX (reduced, $22M), Centessa Pharmaceuticals PLC (sold out, $17.6M), 2seventy bio Inc (sold out, $12.3M), Akero Therapeutics Inc (reduced, $12M).

When was this filing made?

Baker Bros. Advisors filed its 13F for the quarter ending Jun 30, 2025 on Aug 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio, Q2 2025: Baker Bros. Advisors 13F holdings”, data as of 14 August 2025. https://funkfolio.com/gurus/baker-brothers/2025-q2

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Jun 30, 2025.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Jun 30, 2025, filed Aug 14, 2025. Changes compare share counts with the filing for Mar 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $10.3B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 5 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.